Ototoxicity Associated News Today

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA - read this article along with other careers information, tips and advice on BioSpace

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven...

~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin...

(2022-11-11 | TSX:FRX) Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...

01.08.2022 - ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, ... Seite 1